RAPID's Fine Print: FDA and CMS' Newest Alignment Bid Faces Old Questions

article image
ARTICLE SUMMARY:

The new RAPID pathway promises what medtech has chased for over a decade: device authorization and Medicare coverage in unison. But unease about narrow eligibility, an unproven CMS resource base, and the prospect of an unpredictably heavier premarket burden has industry wondering whether RAPID is a real fix or just a new acronym.

The latest effort by FDA and CMS to target one of the holy grails of medtech market access—aligning regulatory approval and Medicare coverage—is getting a mixed response from industry advocates and coverage experts.

It's not for lack of trying. The two agencies have been working since at least 2010 to close the gap between FDA clearance and national coverage for high-value device innovations, and they have a handful of individual successes, and several acronyms, to show for it. What they haven't produced, medtech companies say, is a durable framework matched to the scale of the problem.

Plans for the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway were first announced with some fanfare by the two agencies in April and now, three and-one-half months later, CMS has followed up with an official proposal. For selected FDA-designated Breakthrough Devices, RAPID makes a clear-cut commitment: a proposed Medicare National Coverage Determination (NCD) on the same day that FDA authorizes the device for market, and a final NCD two to three months later. To accomplish that, FDA and CMS pledge to engage with participating companies before they have designed their FDA pivotal trial so the study can be constructed to address both FDA and Medicare coverage requirements.

“RAPID is a step forward but too limited in scope.”

Scott Whitaker, AdvaMed

There is some enthusiasm in the medtech community that RAPID could help big-ticket device innovations get a foothold in the market before funding runs out—and send a signal to investors that breakthrough medtech is a dependable bet. But this isn't the first time the agencies have promised this kind of alignment, and industry generally views the past efforts as too limited to address the scale of the "valley of death" between approval and reimbursement. Some are questioning whether RAPID, as described in CMS' August 11 proposal, will go much further.

“RAPID is a step forward but too limited in scope,” says Scott Whitaker, president and CEO of AdvaMed. The trade association is pressing CMS to remove some limitations on the pathway, which is currently in a 60-day comment period, while working with Congress on legislation to create a more robust, sustainable path to Medicare coverage for Breakthrough Devices.

×



This article is restricted to subscribers only.

Sign in to continue reading.

Questions?

We're here to help! Please contact us at: